External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial.
J UrolApr 28, 2026 (epub)
Clinical ResearchUrology
Alon Lazarovich, Melis Guer, Ferdinand Luger et al.
✦ AI-curated · Sources linked
In 30 seconds
This validation study analyzed data from the OPTIMUM randomized controlled trial to assess the PRI-MUS scoring system's effectiveness in predicting clinically significant prostate cancer (csPCa) in patients undergoing micro-ultrasonography (microUS)-guided biopsy. The study found that at the per-core level, the sensitivity and negative predictive value (NPV) were 72% and 93%, respectively, indicating strong diagnostic performance.
Key findings
- At the per-core level, sensitivity was 72% and NPV was 93% for detecting csPCa.
- At the per-lesion level, sensitivity was 92% and NPV was 83% for detecting csPCa.
- The area under the curve (AUC) for both per-core and per-lesion analyses was 0.78.
Why it matters
The PRI-MUS scoring system provides a reliable method for risk stratification in prostate cancer diagnosis, potentially improving decision-making in biopsy procedures and patient management.